Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Liabilities and Shareholders Equity (2019 - 2025)

Historic Liabilities and Shareholders Equity for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $1.1 billion.

  • Kymera Therapeutics' Liabilities and Shareholders Equity rose 649.39% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 billion, marking a year-over-year increase of 2495.06%. This contributed to the annual value of $978.0 million for FY2024, which is 6986.88% up from last year.
  • Kymera Therapeutics' Liabilities and Shareholders Equity amounted to $1.1 billion in Q3 2025, which was up 649.39% from $1.1 billion recorded in Q2 2025.
  • Over the past 5 years, Kymera Therapeutics' Liabilities and Shareholders Equity peaked at $1.1 billion during Q2 2025, and registered a low of $434.4 million during Q2 2021.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $613.9 million (2023), whereas its average is $718.8 million.
  • As far as peak fluctuations go, Kymera Therapeutics' Liabilities and Shareholders Equity plummeted by 1348.44% in 2023, and later surged by 8734.31% in 2024.
  • Quarter analysis of 5 years shows Kymera Therapeutics' Liabilities and Shareholders Equity stood at $605.9 million in 2021, then fell by 0.46% to $603.1 million in 2022, then decreased by 4.54% to $575.8 million in 2023, then skyrocketed by 69.87% to $978.0 million in 2024, then increased by 12.68% to $1.1 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $1.1 billion for Q3 2025, versus $1.1 billion for Q2 2025 and $918.3 million for Q1 2025.